An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study

Main Article Content

D Thaci
University of L?beck, L?beck, Germany

K Papp
K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada

K Gordon
Medical College of Wisconsin, Milwaukee, WI, USA

A Morita
Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

M Gooderham
SKiN Centre for Dermatology, Queen?s University and Probity Medical Research, Peterborough, ON, Canada

P Foley
The University of Melbourne, St Vincent?s Hospital Melbourne & Probity Medical Research, Skin & Cancer Foundation Inc, Melbourne, Victoria, Australia

E Alemano
Bristol-Myers Squibb, Princeton, NJ, USA

R Kisa
Bristol-Myers Squibb, Princeton, NJ, USA

Y Elbez
Excelya, Boulogne-Billancourt, France

H Ren
Bristol-Myers Squibb, Princeton, NJ, USA

S Banerjee
Bristol-Myers Squibb, Princeton, NJ, USA

Keywords

psoriasis, tyrosine kinase 2 inhibitor

Abstract

Abstract not available.

References

1. Mahil SK et al. Semin Immunopathol. 2016;38:11-27.

2. Armstrong AW et al. PLoS One. 2012;7:e52935.

3. Dubertret L et al. Br J Dermatol. 2006;155:729-736.

4. Finlay AY, Khan GK. Clin Exp Dermatol. 1994;19:210-216.

5. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

6. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl 10):abstract 11L.

7. Harden JL et al. J Autoimmun. 2015;64:66-73.

8. Yao Y et al. PLoS One. 2008;3:e2737.

9. Papp K et al. N Engl J Med. 2018;379:1313-1321.

10. Hongbo Y et al. J Invest Dermatol. 2005;125:659-664.

Article Sidebar

Poster PDF
Published
Nov 9, 2019
DOI https://doi.org/10.25251/skin.3.supp.12

Article Details

How to Cite
[1]
Thaci, D., Papp, K., Gordon, K., Morita, A., Gooderham, M., Foley, P., Alemano, E., Kisa, R., Elbez, Y., Ren, H. and Banerjee, S. 2019. An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S12. DOI:https://doi.org/10.25251/skin.3.supp.12.
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>